• No results found

University of Groningen Tackling challenges to tuberculosis elimination Gröschel, Matthias Ingo Paul

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Tackling challenges to tuberculosis elimination Gröschel, Matthias Ingo Paul"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Tackling challenges to tuberculosis elimination

Gröschel, Matthias Ingo Paul

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Gröschel, M. I. P. (2019). Tackling challenges to tuberculosis elimination: Vaccines, drug-resistance, comorbidities. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen

Behorend bij het proefschrift

“Tackling Challenges to Tuberculosis Elimination Vaccines, Drug-resistance, Comorbidities”

Matthias Gröschel 1st April, 2019

1. The biological phenotype of ESX-1 can be safely leveraged to generate more efficacious recombinant BCG vaccines. This thesis

2. There is a trade-off between virulence and efficacy in live-attenuated vaccines such as BCG. This thesis

3. Immunotherapy for TB through therapeutic vaccines is a promising approach to turn the tide of the TB endemic. This thesis.

4. Sequence-based diagnostics as well as resistance and susceptibility prediction will greatly improve treatment for TB and MDR-TB patients. This thesis.

5. The currently used classification of the Stenotrophomonas maltophilia complex into sensu stricto and lato should be revised as all genotypic groups are able to both colonize and invasively infect humans. This thesis

6. All major S. maltophilia groups are genetically highly diverse which would justify sub-classifying them into new species. This thesis

7. The WHO End TB strategy will inevitably fail as we are approaching a historic high of TB cases.

8. TB elimination will never happen without also addressing co-morbidities and poverty.

9. Constitutive response to when something turns up is yes (Jim Smith) 10. An adult scientist is a kid who never grew up (Neil DeGrasse Tyson)

Referenties

GERELATEERDE DOCUMENTEN

The work described herein was conducted at the Department of Pulmon- ary Diseases & Tuberculosis at the University Medical Center Groningen, University of Groningen

Experimental infection of cattle with Mycobacterium tuberculosis isol- ates shows the attenuation of the human tubercle bacillus for cattle.. Revisiting host preference in

In addition to regulation through co-dependent export with other ESX- 1 substrates, such as the co-dependency between EspA or EspC and EsxA or EsxB, ESX-1 secretion is tightly

Here, by heterologously expressing the esx-1 region of Mycobacterium marinum in BCG, we engineered a low-virulence, ESX- 1-proficient, recombinant BCG (BCG::ESX-1 Mmar) that induces

Further safety and immunogenicity data of the RUTI  R vaccine candidate in humans treated for MDR-TB are required before a Phase III randomised controlled trial can be considered..

Figure 5.2: Clinical trial design. This phase II trial is divided into two sub- sequent cohorts. Cohort A receives vaccination after 16 weeks of treatment and, upon safety analysis

In this pearl, we briefly portray how genome sequencing has transformed and accelerated deliv- ery of tailored treatment to patients with multidrug-resistant (MDR)-TB (defined by

Samen met Jacques van de Ven (is er in Amsterdam ooit iets gebeurd wat jee niet weet?) gaf Willem mij de ruimte mijn eigen weg te vinden, ruimte waarin ik al diee tijd blij